J 2017

Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study

VERHOEF, G., T. ROBAK, H.Q. HUANG, H. PYLYPENKO, N. SIRITANARATKUL et. al.

Basic information

Original name

Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study

Authors

VERHOEF, G. (56 Belgium), T. ROBAK (616 Poland), H.Q. HUANG (156 China), H. PYLYPENKO (804 Ukraine), N. SIRITANARATKUL (764 Thailand), J. PEREIRA (76 Brazil), J. DRACH (40 Austria), Jiří MAYER (203 Czech Republic, guarantor, belonging to the institution), R. OKAMOTO (392 Japan), L.X. PEI (840 United States of America), B. ROONEY (826 United Kingdom of Great Britain and Northern Ireland), A. CAKANA (826 United Kingdom of Great Britain and Northern Ireland), H. van de VELDE (840 United States of America) and F. CAVALLI (756 Switzerland)

Edition

Haematologica, PAVIA, FERRATA STORTI FOUNDATION, 2017, 0390-6078

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

Italy

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 9.090

RIV identification code

RIV/00216224:14110/17:00098741

Organization unit

Faculty of Medicine

DOI

UT WoS

000402490900026

Keywords in English

3 LYM-3002

Tags

Tags

International impact, Reviewed
Změněno: 20/3/2018 18:52, Soňa Böhmová

Abstract

V originále

In the phase 3 LYM-3002 study comparing intravenous VR-CAP with R-CHOP in patients with newly-diagnosed, measurable stage II-IV mantle cell lymphoma, not considered or ineligible for transplant, the median progression-free survival was significantly improved with VR-CAP (24.7 versus 14.4 months with R-CHOP; P<0.001). This post-hoc analysis evaluated the association between the improved outcomes and quality of responses achieved with VR-CAP versus R-CHOP in LYM-3002. Patients were randomized to six to eight 21-day cycles of VR-CAP or R-CHOP. Outcomes included progression-free survival, duration of response (both assessed by an independent review committee), and time to next anti-lymphoma treatment, evaluated by response (complete response/unconfirmed complete response and partial response), MIPI risk status, and maximum reduction of lymph-node measurements expressed as the sum of the product of the diameters. Within each response category, the median progression-free survival was longer for patients given VR-CAP than for those given R-CHOP (complete response/unconfirmed complete response: 40.9 versus 19.8 months; partial response: 17.1 versus 11.7 months, respectively); similarly, the median time to next anti-lymphoma treatment was longer among the patients given VR-CAP than among those treated with R-CHOP (complete response/unconfirmed complete response: not evaluable versus 26.6 months; partial response: 35.3 versus 24.3 months). Within the complete/unconfirmed complete and partial response categories, improvements in progression-free survival, duration of response and time to next anti-lymphoma treatment were more pronounced in patients with low- and intermediate-risk MIPI treated with VR-CAP than with R-CHOP. In each response category, more VR-CAP than R-CHOP patients had a sum of the product of the diameters nadir of 0 during serial radiological assessments. Results of this post-hoc analysis suggest a greater duration and quality of response in patients treated with VR-CAP in comparison with those treated with R-CHOP, with the improvements being more evident in patients with low-and intermediate-risk MIPI. LYM-3002 ClinicalTrials.gov: NCT00722137.